Authors: Papadopoulos, KP Egorin, MJ Huang, M Troxel, AB Kaufman, E Balmaceda, CM Vahdat, LT Hesdorffer, CS

Citation: Kp. Papadopoulos et al., The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer, CANC CHEMOT, 47(1), 2001, pp. 45-50

Authors: Papadopoulos, KP Ayello, J Reiss, RF Troxel, A Kaufman, E Vahdat, LT Antman, KH Hesdorffer, CS

Citation: Kp. Papadopoulos et al., CD34(+) cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer, J HEMATH ST, 8(4), 1999, pp. 357-363

Authors: Lee, RT Oster, MW Balmaceda, C Hesdorffer, CS Vahdat, LT Papadopoulos, KP

Citation: Rt. Lee et al., Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel, ANN ONCOL, 10(10), 1999, pp. 1245-1247

Authors: Papadopoulos, KP Balmaceda, C Fetell, M Kaufman, E Vahdat, LT Bruce, J Sisti, M Isaacson, S De LaPaz, R Savage, DG Troxel, A Antman, KH Hesdorffer, CS

Citation: Kp. Papadopoulos et al., A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors, J NEURO-ONC, 44(2), 1999, pp. 155-162